Answers are grounded in this paper and cite their sources.
Cardiogenic shock (CS) is a complex and dreadful condition for which effective treatments remain unclear. The concerningly high mortality rate of CS emphasizes a need for developing effective therapies to reduce its mortality and reverse its detrimental course. This article aims to provide an updated and evidence-based review of the pathophysiology of CS and the related pharmacotherapeutics with a special focus on vasoactive and inotropic agents.
No takes yet. Share an insight, caveat, or question.
Hussein et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: